Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01472991 · ClinicalTrials.gov registry record · Phase 2
Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 study, sponsored by Targacept.
- Completed
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
NCT01472991 is a Phase 2 study that has completed, run by Targacept. The registered enrollment target is 250 participants.
The verdict
NCT01472991, a Phase 2 study, has completed, sponsored by Targacept.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
Study Summary
Study is to assess if TC-5619 improves symptoms for adults diagnosed with the inattentive-predominant subtype of ADHD over a 4-week treatment period.
Interventions
- DRUG Placebo
- DRUG TC-5619-238 5mg
- DRUG TC-5619-238 25mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01472991
The ClinicalTrials.gov registry entry for NCT01472991 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Targacept, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01472991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01472991 about?
NCT01472991 is a clinical study titled "Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)". Study is to assess if TC-5619 improves symptoms for adults diagnosed with the inattentive-predominant subtype of ADHD over a 4-week treatment period.
What is the current status of trial NCT01472991?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2011-11. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01472991?
The interventions under investigation include: Placebo (DRUG), TC-5619-238 5mg (DRUG), TC-5619-238 25mg (DRUG).
Who is sponsoring clinical trial NCT01472991?
This trial is sponsored by Targacept, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.